Preamble
There is no preface, foreword, or opening statement to this symposium.

Aims
Not stated.

Contents (ix + 244 pages)
Acknowledgment
Contributors
I. Statistical methods
   1. Applications of large-sample sequential tests to the analysis of survival data (DR Jones, J Whitehead)
   2. Advantages and defects of single-centre and multicenter clinical trials (D Machin, MJ Staquet, RJ Sylvester)
   3. The experience of the EORTC-Gnotobiotic project group in planning, organizing, performing, and evaluating cooperative clinical trials (W Gaus)
   4. Survival studies using a computer-based hospital registry of 29,000 cancer patients (MK Parmer)
   5. Controlled clinical trials and the importance of medical judgment (R Burkhardt, G Kienle)
   6. Heterogeneity and standardization in clinical trials (R Simon)
   7. Interim analysis and early results in clinical trials (C Hill, H Sancho-Garnier)
   8. Feedback of data to participants during clinical trials (RJ Prescott)
   9. Can sequential methods be used for the analysis of cancer clinical trials? (SJ Pocock)
  10. The necessity and justification of randomized clinical trials (DP Byar)
II. Toxicity and therapy
   11. Quantitative and qualitative prediction of toxicity from animals to human (A Goldin, M Bozencweig, AM Guarino, P Schein)
   12. Thoughts on a role for cell kinetics in cancer chemotherapy (L Norton)
   14. Protected environment and prophylactic antibiotics as an adjunct to cancer chemotherapy: how useful? (J Klastersky)
   15. Controversies in screening for early diagnosis of breast cancer (AM Stark)
   16. The MRC trial of low-dose preoperative radiotherapy in operable rectal cancer (SJ Arnott)
   17. Preoperative radiotherapy for colorectal cancer – Veterans Administration group[ studies (GA Higgins)
   18. Preoperative radiotherapy in rectal cancer (MW Stearns, Jr)
   19. The clinical relevance of histopathologic classification in non-Hodgkin’s lymphoma (SE Come, CP Canellos)
   20. Clinical relevance of the Kiel classification of non-Hodgkin lymphomas: preliminary results of a prospective multicentric study (G Brittinger et al)
   21. Management of patients with early stages of ovarian carcinoma (E van der Schueren, D Gonzalez, K Breur)
   22. Immediate versus delayed lymph-node dissection in stage I melanoma of the limbs (U Veronesi)
23. Efficacy of elective regional lymph-node dissection in primary (stage I) malignant melanoma (FJ Lejeune)
24. Levamisole immunotherapy: basis and clinical trials in cancer patients (F Martin)
25. Clinical trials of levamisole in humans (DP Byar)

Index

Authors
The editors are Henri J Tagnon MD (location not stated) and Maurice J Staquet MD (EORTC Data Center, Institut Jules Bordet, Bruxelles, Belgium). The contributors are: SJ Arnott (Western General Hospital, Edinburgh, Great Britain); K Breur (Wilhelmina Gasthuis, Amsterdam, The Netherlands); G Brittinger (Hämatologische Abteilung, Medizinische Universitätsklinik Essen, Essen, Western Germany); R Buckhardt (Gemeinnütziges Gemeinschaftskrankenhaus Herdecke, Herdecke, Western Germany); DP Byar (Head, Clinical and Diagnostic Section, Biometry Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA); GP Canellos (Chief of Medicine, Sidney Farber Cancer Institute, Harvard Medical School, Boston, MA, USA); SE Come (Division of Medical Oncology, Sidney Farber Cancer Institute, Harvard Medical School, Boston, MA, USA); W Gaus (Universität Ulm, Klinische Dokumentation, Ulm, Western Germany); A Goldin (Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA); D Gonzalez (Wilhelmina Gasthuis, Amsterdam, The Netherlands); AM Guarino (Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA); GA Higgins (Veterans Administration Hospital, Washington, DC, USA); C Hill (Institut Gustave Roussy, Villejuif, France); DR Jones (Institute of Cancer Research, Division of Epidemiology, Sutton, Surrey, Great Britain); Kiel Lymphoma Group, Division of Haematology, Department of Medicine, Universität Essen, Essen, Western Germany); G Kienle (Gemeinnütziges Gemeinschaftskrankenhaus Herdecke, Herdecke, Western Germany); J Klastersky (Institut Jules Bordet, Bruxelles, Belgium); FJ Lejeune (Institut Jules Bordet, Bruxelles, Belgium); D Machin (EORTC Data Center, Institut Jules Bordet, Bruxelles, Belgium); F Martin (Laboratoire d’Immunologie et de Médecine Expérimentale, Faculté de Médecine, Dijon, France); L Norton (Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, NY, USA); M Palmer (Christie Hospital, and Holt Radium Institute, Withington, Manchester, Great Britain); SJ Pocock (Department of Clinical Epidemiology and Social Medicine, The Royal Free Hospital, London, Great Britain); RJ Prescott (Medical Computing and Statistics Unit, Medical School, Edinburgh, Great Britain); M Rozenweig (Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA); H Sancho-Garnier (Institut Gustave Roussy, Villejuif, France); P Schein (Division of Medical Oncology, Vincent T Lombardi Cancer Research Center, Georgetown University School of Medicine, Washington, DC, USA); R Simon (Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA); AM Stark (Department of Gynaecological Oncology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, Great Britain); MW Stearns Jr (Chief, Rectum and Colon Service, Memorial Sloan Kettering, Cancer Center, New York, NY, USA); RJ Sylvester (EORTC Data Center, Institut Jules Bordet, Bruxelles, Belgium); E van der Schueren (Wilhelmina Gasthuis, Amsterdam, The Netherlands); LM van Putten (Radiobiological Institute TNO, Rijswijk, The Netherlands); U Veronesi (Istituto Nazionale dei Tumori, Milano, Italy); and, J Whitehead (Department of Mathematics, Chelsea College, University of London, London, Great Britain).